Tag Archives: test

Next SpaceX Flight Test Scheduled for Launch this Month

Posted on by
Reply

Starship was first launched on April 20, 2023.

Jonathan Newton/The Washington Post via Getty Images

SpaceX is preparing to launch its massive Starship rocket for the third time. However, the exact launch date will not be announced until the US government's Federal Aviation Administration (FAA) completes its investigation into why the previous launch (November 2023) failed to reach orbit.

The Starship rocket's first test launch in April 2023 went out of control due to some engine problems. These failures triggered an automatic flight termination system designed to safely detonate the rocket. It failed, and the rocket continued to tumble until it collapsed. It didn't reach space.

The accident damaged the launch pad and scattered debris over a vast area. SpaceX will begin second Starship test launch in November 2023 after launch facility repairs and updates are made and the FAA certifies that sufficient work has been done to prevent similar damage from occurring again did.

That didn't work either. Everything seemed fine for a few minutes. The rocket reaches space, but then its engine begins to fail and it explodes. Now SpaceX has to build a new rocket, and the FAA has to give it permission to fly.

“We expect that license to be issued in February. So it will be [flight] The third time will happen in February of this year,” SpaceX official Jessica Jensen said at a press conference on January 9th.

Ultimately, Starship is intended to transport astronauts to and from the moon. NASA has selected this rocket for the Artemis III and IV missions planned for 2026 and 2028. The massive rocket could carry astronauts to Mars as early as 2029, SpaceX CEO Elon Musk said. But first, Starship must reach space without exploding or breaking apart, and its third flight will be an important test.

topic:

Source: www.newscientist.com

Revolutionary New Test Promises Breakthrough in Acute Myeloid Leukemia Treatment

Posted on by
Reply

A breakthrough assay to detect acute myeloid leukemia (AML) through a KMT2A gene fusion promises to enhance diagnosis and treatment and represents a major advance in leukemia research.


The researchers Accuracy
Detecting specific molecular markers within leukemia cells has the potential to significantly improve the assessment of measurable residual disease. This advancement will enable better-informed treatment decisions and ultimately improve patient outcomes.

A new assay that detects unique molecular markers in patients with acute myeloid leukemia (AML) could revolutionize how the disease is detected and treated, according to a recently published new report. Molecular Diagnostic Journal Published by Elsevier. This assay may improve the detection of AML due to factors such as: Kuomintang 2A Gene fusions can impact treatment decision-making, assessment of response to treatment, and long-term monitoring.

AML is a rare, aggressive blood cancer that is diagnosed in approximately 120,000 people worldwide each year. Detecting residual disease during treatment is essential to determine prognosis and guide treatment decisions.Currently, methods to detect measurable residual disease (MRD) during treatment of AML include bone marrow morphology, multiparameter flow cytometry (MPFC), and DNA Sequencing.

Morphological evaluation detects leukemic cells only with a detection limit of 5%. Although MPFC has a more sensitive detection limit of 0.01% to 0.001%, it is difficult to implement and interpret and is not standardized across laboratories. DNA sequencing approaches can identify leukemic cells by somatic mutation profiles, but are expensive and can be confounded by clonal hematopoiesis in nonleukemic blood cells.

Breakthrough progress in leukemia research

“We’ve seen a lot of research in this field,” explained lead researcher Dr. Grant A. Challen, of the Department of Oncology at Washington University School of Medicine in St. Louis. Normally absent in healthy cells. Other diseases such as chronic myeloid leukemia (CML) can already be tracked by standard BCR-ABL fusions, and sensitive detection of these fusions has revolutionized the way CML is treated. . For AML patients whose disease is caused by oncogenic fusions, the KMT2A fusion is a molecular marker that can be exploited for sensitive MRD detection. Therefore, we wanted to develop a platform for sensitive KMT2A fusion detection to improve detection and treatment methods for this disease. ”

Researchers have developed a new droplet digital PCR assay that allows for high sensitivity. Kuomintang 2A Fusion detection with the five most common fusion partners.At least 80 are known Kuomintang 2A There are fusion partners, but approximately 80% of fusions involve only 5 partners – AF9, AF6, AF4, Elleand English. They benchmarked the assay in human cell lines and patient samples and demonstrated sensitivity and specificity. Kuomintang 2A Fusion detection.

This assay detects these fusions by splitting cDNA molecules into microfluidic droplets and assaying them using primers and probes that generate a positive signal only when the fused transcript is present. Researchers were able to combine multiple primer/probe sets targeting different fusions into a pooled fusion detection reagent. they again, Kuomintang 2A Fusions in patient samples are known to be present Kuomintang 2A fusion.

Implications for AML treatment and future research

Dr. Challen said: This assay can be easily extended to include additional oncogenic fusions. This has potential implications for treatment decision-making and assessment of response to treatment. Knowing whether treatment is effective is critical to deciding when to escalate treatment or perform a hematopoietic stem cell transplant. ”

“This is a powerful new tool for highly sensitive KMT2A fusion detection and can be directly applied to disease detection in leukemia patients caused by these fusions. This fills a void in oncogenic fusion detection. , we offer several technical improvements. This assay is also highly scalable, and additional fusions can be easily added to the assay to expand coverage of other oncogenic fusions. We is improving blood cancer detection one drop at a time.”

Reference: “Droplet Digital PCR for Oncogenic KMT2A Fusion Detection” by Andrew L. Young, Hannah C. Davis, and Grant A. Challen, October 7, 2023. Molecular Diagnostic Journal.
DOI: 10.1016/j.jmoldx.2023.09.006

This research was funded by: National Institutes of Health and the Leukemia and Lymphoma Society.

Source: scitechdaily.com

NASA’s Exciting Test Phase for Dream Chaser

Posted on by
Reply

NASA and Sierra Space are making progress toward the company’s Dream Chaser spacecraft’s maiden flight to the International Space Station. The unmanned cargo spaceplane is scheduled to begin demonstration missions to orbital complexes in 2024 as part of NASA’s commercial resupply services. Credit: Sierra Space

NASA and Sierra Space are testing the Dream Chaser spacecraft at the Neil Armstrong Test Facility, with a focus on environmental simulation for future ISS missions. After testing, the spacecraft will head to Kennedy Space Center for launch in 2024.

NASA and Sierra Space are preparing for the maiden flight of their Dream Chaser spacecraft. international space station. Dream Chaser and its accompanying cargo module “Shooting Star” NASA’s Neil Armstrong Test Facility It will fly in Sandusky, Ohio, for environmental testing, scheduled to begin in mid-December ahead of its first flight scheduled for early 2024.

State-of-the-art testing equipment

The Neil Armstrong Test Facility, part of NASA’s Glenn Research Center in Cleveland, has multiple test facilities including the Space Environment Complex and the Space Propulsion Facility, both of which will be home to Dream Chaser. The complex includes a mechanical vibration facility that exposes test articles to the harsh conditions of launch.

During Armstrong’s stay, the Dream Chaser winged spacecraft will be stacked atop the Shooting Star cargo module on a vibration table, experiencing vibrations similar to those experienced during liftoff or atmospheric re-entry.

NASA and Sierra Space are making progress toward the company’s Dream Chaser spacecraft’s maiden flight to the International Space Station. The unmanned cargo spaceplane is scheduled to begin demonstration missions to orbital complexes in 2024 as part of NASA’s commercial resupply services. Credit: Sierra Space/Shay Saldana

Rigorous space simulation

After vibration testing, Dream Chaser will be moved to the propulsion facility for thermal vacuum testing. Dream Chaser is placed in a vacuum and exposed to low ambient pressure, low background temperature, and simulated dynamic solar heating, simulating the environment the spacecraft will encounter during its mission. This facility is the only facility capable of testing full-scale upper stage rockets and rocket engines under simulated space conditions and conducting high-temperature fires.

After testing at Armstrong, Dream Chaser will be transported to NASA’s Kennedy Space Center in Florida for further launch preparations, and is currently scheduled to launch in the first half of 2024.

Source: scitechdaily.com